IL62552A0
(en)
|
1980-04-03 |
1981-06-29 |
Biogen Nv |
Dna sequences,recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
|
IT1185503B
(it)
*
|
1984-01-11 |
1987-11-12 |
Univ New York |
Cloni di odna di eritropietina umana
|
IL77081A
(en)
*
|
1984-12-04 |
1999-10-28 |
Genetics Inst |
AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
|
JPS62501010A
(ja)
|
1984-12-04 |
1987-04-23 |
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド |
エリトロポエチンの生産方法
|
US4677195A
(en)
*
|
1985-01-11 |
1987-06-30 |
Genetics Institute, Inc. |
Method for the purification of erythropoietin and erythropoietin compositions
|
US4732889A
(en)
*
|
1985-02-06 |
1988-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
|
US4745099A
(en)
*
|
1985-02-06 |
1988-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for the treatment of the anemia of malignant tumors
|
GB2177914B
(en)
*
|
1985-06-04 |
1989-10-25 |
Chugai Pharmaceutical Co Ltd |
A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
|
IL79176A
(en)
*
|
1985-06-20 |
1992-06-21 |
Kirin Amgen Inc |
Process for the recovery of erythropoietin from a fluid
|
JPS63500636A
(ja)
*
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするdna
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US6004548A
(en)
*
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
US4935350A
(en)
*
|
1985-11-18 |
1990-06-19 |
Amgen |
Materials and methods for controlling plasmid copy number and stability
|
JPS62171696A
(ja)
*
|
1986-01-23 |
1987-07-28 |
Sumitomo Chem Co Ltd |
ヒトエリスロポエチンの製造方法
|
EP0236059B1
(en)
*
|
1986-02-27 |
1994-04-27 |
Snow Brand Milk Products Co. Ltd. |
Preparation of erythropoietin-producing cells and production process of erythropoietin using same
|
DK173067B1
(da)
|
1986-06-27 |
1999-12-13 |
Univ Washington |
Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
|
GR871029B
(en)
|
1986-07-14 |
1987-11-02 |
Genetics Inst |
Novel osteoinductive factors
|
US4954437A
(en)
*
|
1986-09-15 |
1990-09-04 |
Integrated Genetics, Inc. |
Cell encoding recombinant human erythropoietin
|
US5013718A
(en)
*
|
1986-11-21 |
1991-05-07 |
Amgen, Inc. |
Method for treating iron overload using EPO
|
WO1988005466A2
(en)
*
|
1987-01-15 |
1988-07-28 |
Codon |
Tandem gene eukaryotic expression vectors
|
US4835260A
(en)
*
|
1987-03-20 |
1989-05-30 |
Genetics Institute, Inc. |
Erythropoietin composition
|
JP2791418B2
(ja)
|
1987-12-02 |
1998-08-27 |
株式会社ミドリ十字 |
異種蛋白質の製造方法、組換えdna、形質転換体
|
DE3923963A1
(de)
*
|
1989-07-20 |
1991-01-31 |
Behringwerke Ag |
Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
|
DE3924746A1
(de)
*
|
1989-07-26 |
1991-01-31 |
Behringwerke Ag |
Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
|
US6932968B1
(en)
|
1989-07-26 |
2005-08-23 |
Dade Behring Marburg Gmbh |
Erythropoietin (EPO) peptides and antibodies directed against these
|
US7217689B1
(en)
|
1989-10-13 |
2007-05-15 |
Amgen Inc. |
Glycosylation analogs of erythropoietin
|
AU646822B2
(en)
*
|
1989-10-13 |
1994-03-10 |
Kirin-Amgen Inc. |
Erythropoietin isoforms
|
DE4115722A1
(de)
*
|
1991-05-14 |
1992-11-19 |
Boehringer Mannheim Gmbh |
Serumfreies medium zur kultivierung von saeugerzellen
|
US5968502A
(en)
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
US6270989B1
(en)
|
1991-11-05 |
2001-08-07 |
Transkaryotic Therapies, Inc. |
Protein production and delivery
|
PT101031B
(pt)
|
1991-11-05 |
2002-07-31 |
Transkaryotic Therapies Inc |
Processo para o fornecimento de proteinas por terapia genetica
|
US5728536A
(en)
*
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
EP0659759B1
(en)
*
|
1992-09-09 |
1999-12-08 |
Nippon Kayaku Kabushiki Kaisha |
Novel physiologically active substance nk175203, process for producing the same, and pharmaceutical use thereof
|
AU6709794A
(en)
*
|
1993-04-21 |
1994-11-08 |
Brigham And Women's Hospital |
Erythropoietin muteins with enhanced activity
|
IL192290A0
(en)
*
|
1993-08-17 |
2008-12-29 |
Kirin Amgen Inc |
Erythropoietin analogs
|
US8192955B1
(en)
*
|
1994-01-03 |
2012-06-05 |
Genentech, Inc. |
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
|
US5888774A
(en)
*
|
1994-12-19 |
1999-03-30 |
Cangene Corporation |
Recombinant DNA molecules and expression vectors for erythropoietin
|
IL118201A
(en)
*
|
1995-05-11 |
2004-12-15 |
Roche Diagnostics Gmbh |
Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
|
CA2223833C
(en)
*
|
1995-06-07 |
2010-12-21 |
Nicholas C. Wrighton |
Compounds and peptides that bind to the erythropoietin receptor
|
EP0833934B2
(en)
|
1995-06-15 |
2012-08-15 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP0752474A1
(en)
*
|
1995-07-07 |
1997-01-08 |
Boehringer Mannheim Gmbh |
Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
|
EP0837942A1
(en)
*
|
1995-07-07 |
1998-04-29 |
Boehringer Mannheim Gmbh |
Nucleic acid coding for cmp-n-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
|
IL125839A0
(en)
|
1996-03-14 |
1999-04-11 |
Genentech Inc |
Uses of gdnf and gdnf receptor
|
GB2318352A
(en)
*
|
1996-06-25 |
1998-04-22 |
Dejan Markovic |
Polypeptides mimicking the activity of human erythropoietin
|
US5952226A
(en)
*
|
1996-11-05 |
1999-09-14 |
Modex Therapeutiques |
Hypoxia responsive EPO producing cells
|
US6573055B2
(en)
*
|
1997-04-21 |
2003-06-03 |
Glycozyme, Inc. |
Determination of recombinant glycosylated proteins and peptides in biological fluids
|
US6475725B1
(en)
*
|
1997-06-20 |
2002-11-05 |
Baxter Aktiengesellschaft |
Recombinant cell clones having increased stability and methods of making and using the same
|
DE19729769A1
(de)
|
1997-07-11 |
1999-01-14 |
Cardiogene Gentherapeutische S |
Transfektionssystem, seine Herstellung und Verwendung in der somatischen Gentherapie
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
US6740503B1
(en)
|
1997-09-26 |
2004-05-25 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
US6897066B1
(en)
*
|
1997-09-26 |
2005-05-24 |
Athersys, Inc. |
Compositions and methods for non-targeted activation of endogenous genes
|
PT1023442E
(pt)
*
|
1997-10-16 |
2011-02-25 |
Synageva Biopharma Corp |
Vectores compreendendo um promotor específico do magno para transgénese aviária
|
CA2312188C
(en)
|
1997-12-08 |
2010-06-29 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US7037663B2
(en)
*
|
1998-02-19 |
2006-05-02 |
Eastern Virginia Medical School |
Human zona pellucida protein 3 and uses thereof
|
DE69922489T2
(de)
*
|
1998-02-19 |
2005-12-15 |
Eastern Virginia Medical School |
Rekombinantes aktives humanes Zona Pellucida
|
ES2224299T3
(es)
|
1998-02-23 |
2005-03-01 |
Cilag Ag International |
Dispersion liposomal de eritroyetina.
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
KR100434729B1
(ko)
*
|
1998-03-18 |
2004-11-03 |
주식회사 엘지생명과학 |
천연 추출물을 첨가하여 중국햄스터 난소 유래세포에서 에리스로포이에틴의 생산 증대방법
|
JP2002509729A
(ja)
*
|
1998-03-27 |
2002-04-02 |
サイトス バイオテクノロジー アーゲー |
誘導性のアルファウイルス遺伝子発現系
|
AR019025A1
(es)
|
1998-04-09 |
2001-12-26 |
Roche Diagnostics Gmbh |
Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
|
CA2328076C
(en)
*
|
1998-04-15 |
2009-10-06 |
Lexigen Pharmaceuticals Corporation |
Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
|
CA2326384A1
(en)
*
|
1998-04-22 |
1999-10-28 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
US20050181482A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
DK1088084T3
(da)
*
|
1998-06-15 |
2007-01-29 |
Gtc Biotherapeutics Inc |
Erythropoietin analog-humant serumalbumin fusionsprotein
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
WO2000006205A1
(en)
|
1998-07-29 |
2000-02-10 |
Invitrogen Corporation |
Regulated expression of recombinant proteins using rna viruses
|
EP0984062A1
(en)
*
|
1998-09-04 |
2000-03-08 |
Cytos Biotechnology AG |
Production of human erythropoietin
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US7304150B1
(en)
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
BR9905868A
(pt)
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
|
BR9905867A
(pt)
*
|
1998-11-06 |
2001-01-23 |
Bio Sidus S A |
Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
BR9917606A
(pt)
|
1998-11-06 |
2002-12-31 |
Bio Sidus S A |
Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
|
DE19857609A1
(de)
|
1998-12-14 |
2000-06-15 |
Hannelore Ehrenreich |
Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
DE19905501B4
(de)
|
1999-02-10 |
2005-05-19 |
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie |
Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
|
US20040010134A1
(en)
*
|
2000-04-12 |
2004-01-15 |
Rosen Craig A. |
Albumin fusion proteins
|
US7309687B1
(en)
|
1999-04-13 |
2007-12-18 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
US8236561B2
(en)
*
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
US20050170463A1
(en)
*
|
1999-04-15 |
2005-08-04 |
Abraham Bout |
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
|
US7604960B2
(en)
*
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
US6855544B1
(en)
*
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
US6831060B2
(en)
|
1999-05-07 |
2004-12-14 |
Genentech, Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
MXPA01011264A
(es)
*
|
1999-05-07 |
2002-07-02 |
Genentech Inc |
Nuevos polipeptidos de eritropoyetina de chimpance (chepo) y aciodos nucleicos que codifican los mismos.
|
US6555343B1
(en)
|
1999-05-07 |
2003-04-29 |
Genentech Inc. |
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
|
AT409379B
(de)
|
1999-06-02 |
2002-07-25 |
Baxter Ag |
Medium zur protein- und serumfreien kultivierung von zellen
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US6737519B1
(en)
|
1999-07-30 |
2004-05-18 |
Genome Therapeutics Corporation |
Human genes relating to respiratory diseases and obesity
|
DK1200479T3
(da)
*
|
1999-08-09 |
2006-05-15 |
Emd Lexigen Res Ct Corp |
Multiple cytokin-antistof-komplekser
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
US6703480B1
(en)
|
1999-11-24 |
2004-03-09 |
Palani Balu |
Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
|
US7521220B2
(en)
*
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
US7527961B2
(en)
*
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
WO2001042442A2
(en)
|
1999-12-10 |
2001-06-14 |
Cytos Biotechnology Ag |
Activation of endogenous genes by genomic introduction of a replicon
|
WO2001058957A2
(en)
*
|
2000-02-11 |
2001-08-16 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1299819A2
(en)
*
|
2000-05-12 |
2003-04-09 |
Cyril John Higgins |
Method of organized retrieval of world-wide web pages
|
MXPA02012734A
(es)
*
|
2000-06-29 |
2003-04-25 |
Merck Patent Gmbh |
Mejoramiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citocina, mediante tratamiento combinado con agentes mejoradores de la captacion de inmunocitocina.
|
AU2001273432A1
(en)
*
|
2000-07-13 |
2002-01-30 |
Invitrogen Corporation |
Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
|
US7645898B2
(en)
*
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US7855229B2
(en)
*
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
CA2423093C
(en)
|
2000-09-25 |
2013-09-17 |
Valentis, Inc. |
Improved system for regulation of transgene expression
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
BR0116381A
(pt)
|
2000-12-20 |
2004-02-25 |
Hoffmann La Roche |
Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
|
US7767643B2
(en)
*
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
US6531121B2
(en)
|
2000-12-29 |
2003-03-11 |
The Kenneth S. Warren Institute, Inc. |
Protection and enhancement of erythropoietin-responsive cells, tissues and organs
|
KR100399337B1
(ko)
*
|
2001-02-07 |
2003-09-26 |
드림바이오젠 주식회사 |
단백질의 무세포 번역후수식법
|
KR100900176B1
(ko)
|
2001-03-07 |
2009-06-02 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
US6992174B2
(en)
*
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
CA2446087C
(en)
|
2001-05-03 |
2013-06-18 |
Stephen D. Gillies |
Recombinant tumor specific antibody and use thereof
|
WO2002097038A2
(en)
*
|
2001-05-25 |
2002-12-05 |
Human Genome Sciences, Inc. |
Chemokine beta-1 fusion proteins
|
EP1421104A4
(en)
*
|
2001-08-02 |
2005-08-24 |
Trinity Biomedical Technology |
HUMANE ZONA PELLUCIDA PROTEINS AND METHOD FOR THEIR USE IN THE DIAGNOSIS OF MALE INFERENCE
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
US7048934B2
(en)
*
|
2001-08-30 |
2006-05-23 |
Stem Cell Therapeutics Inc. |
Combined regulation of neural cell production
|
JP4906231B2
(ja)
|
2001-09-14 |
2012-03-28 |
ステム セル セラピューティクス インコーポレイテッド |
プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
|
WO2003024471A2
(en)
*
|
2001-09-18 |
2003-03-27 |
Stem Cell Therapeutics Inc. |
Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
|
KR20040065231A
(ko)
*
|
2001-11-28 |
2004-07-21 |
산도즈 게엠베하 |
세포 배양 방법
|
AU2002357784B2
(en)
*
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
US20070161608A1
(en)
*
|
2001-12-06 |
2007-07-12 |
Dalton James T |
Selective androgen receptor modulators for treating muscle wasting
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
EP1465987B1
(en)
*
|
2001-12-07 |
2008-01-23 |
Crucell Holland B.V. |
Production of viruses, viral isolates and vaccines
|
DK1463751T3
(da)
*
|
2001-12-21 |
2013-08-26 |
Human Genome Sciences Inc |
Albuminfusionsproteiner.
|
WO2003059934A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR100982922B1
(ko)
|
2002-01-17 |
2010-09-20 |
론자 바이올로직스 피엘씨 |
단백질을 생산할 수 있으며 무글루타민 배지에서 성장할 수있는 글루타민-요구성 인간세포
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
US20040009902A1
(en)
*
|
2002-05-13 |
2004-01-15 |
Irving Boime |
CTP extended erythropoietin
|
CA2491567A1
(en)
*
|
2002-07-01 |
2004-01-08 |
The Kenneth S. Warren Institute, Inc. |
Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
|
EP2287288B1
(en)
|
2002-07-09 |
2012-11-07 |
Baxter International Inc. |
Animal protein free media for cultivation of cells
|
DE10234192B4
(de)
|
2002-07-26 |
2009-11-26 |
Epoplus Gmbh Co.Kg |
Verwendung von Erythropoetin
|
CA2492442A1
(en)
*
|
2002-07-31 |
2004-02-05 |
Stem Cell Therapeutics Inc. |
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
|
WO2004020576A2
(en)
*
|
2002-08-31 |
2004-03-11 |
Cj Corp. |
Glycosylated human granulocyte colony-stimulating factor (g-csf) isoform
|
AU2003263552A1
(en)
*
|
2002-09-09 |
2004-03-29 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
EP1681303B1
(en)
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
DE20321793U1
(de)
|
2002-09-11 |
2010-06-02 |
Fresenius Kabi Deutschland Gmbh |
Hydroxyalkylstärke-Derivate
|
JP2006516534A
(ja)
|
2002-09-11 |
2006-07-06 |
フレセニウス・カビ・ドイッチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Has化ポリペプチド、特にhas化エリスロポエチン
|
AU2003273413A1
(en)
|
2002-10-08 |
2004-05-04 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
JP4494977B2
(ja)
*
|
2002-12-17 |
2010-06-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
|
EP1594530A4
(en)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
AR043017A1
(es)
*
|
2003-02-03 |
2005-07-13 |
Japan Immuno Inc |
Vector de alta expresion para celulas animales
|
WO2004091495A2
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
US7459152B2
(en)
*
|
2003-04-23 |
2008-12-02 |
Rush University Medical Center |
Erythropoietin administration to improve graft survival
|
CN101328473B
(zh)
*
|
2003-05-09 |
2012-05-02 |
克鲁塞尔荷兰公司 |
E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
|
MXPA05012316A
(es)
*
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Peptidos novedosos que se unen al receptor de la eritropoyetina.
|
CA2525399A1
(en)
*
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
|
WO2004101611A2
(en)
*
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Peptides that bind to the erythropoietin receptor
|
JP2007530440A
(ja)
*
|
2003-05-12 |
2007-11-01 |
アフィーマックス・インコーポレイテッド |
新規ポリ(エチレングリコール)修飾化合物およびその用途
|
ATE469920T1
(de)
*
|
2003-05-23 |
2010-06-15 |
Crucell Holland Bv |
Herstellung von rekombinanten igm in den per.c6 zellen
|
KR100610003B1
(ko)
|
2003-06-10 |
2006-08-08 |
주식회사 엘지생명과학 |
혈청 알부민을 함유하지 않는 안정한 인 에리쓰로포이에틴용액 제형
|
EP2311994A1
(en)
*
|
2003-08-01 |
2011-04-20 |
Life Technologies Corporation |
Compositions and methods for preparing short RNA molecules and other nucleic acids
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
EA010650B1
(ru)
|
2003-09-29 |
2008-10-30 |
Уоррен Фармасьютикалз, Инк. |
Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
|
ATE469654T1
(de)
|
2003-12-30 |
2010-06-15 |
Augustinus Bader |
Verwendung des erythropoietins zur regeneration von lebergewebe
|
AU2004313245B2
(en)
|
2003-12-30 |
2011-04-14 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
|
WO2005063808A1
(en)
*
|
2003-12-31 |
2005-07-14 |
Merck Patent Gmbh |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
DE102004004509B4
(de)
|
2004-01-23 |
2010-07-01 |
Epoplus Gmbh Co.Kg |
Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
|
US7846898B2
(en)
*
|
2004-02-13 |
2010-12-07 |
Stem Cell Therapeutics Corp. |
Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
|
US7255288B2
(en)
*
|
2004-03-08 |
2007-08-14 |
Wan Shan Chan |
Aroma therapy for fountain
|
EP2336192A1
(en)
|
2004-03-11 |
2011-06-22 |
Fresenius Kabi Deutschland GmbH |
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
|
EP2279752A3
(en)
|
2004-03-11 |
2011-08-24 |
Fresenius Kabi Deutschland GmbH |
Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US20110237664A1
(en)
*
|
2004-06-07 |
2011-09-29 |
Dalton James T |
Selective androgen receptor modulators for treating diabetes
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US20060094104A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Leopold Grillberger |
Animal protein-free media for cultivation of cells
|
MX2007005777A
(es)
*
|
2004-11-11 |
2007-07-20 |
Affymax Inc |
Peptidos novedosos que se unen al receptor de eritropoietina.
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
WO2006061853A2
(en)
*
|
2004-12-10 |
2006-06-15 |
Serum Institute Of India Limited |
Novel erythropoietic compounds and a process for producing erythropoietic compounds
|
US7714114B2
(en)
*
|
2005-02-16 |
2010-05-11 |
Nektar Therapeutics |
Conjugates of an EPO moiety and a polymer
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
WO2007027582A2
(en)
|
2005-08-31 |
2007-03-08 |
University Of Tennessee Research Foundation |
Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
|
EP1762250A1
(en)
|
2005-09-12 |
2007-03-14 |
Fresenius Kabi Deutschland GmbH |
Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
|
KR20080074108A
(ko)
|
2005-09-27 |
2008-08-12 |
스템 셀 테라퓨틱스 코포레이션 |
프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
|
US9388382B2
(en)
*
|
2005-10-05 |
2016-07-12 |
The Board Of Trustees Of The University Of Illinois |
Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
|
JP2009517009A
(ja)
*
|
2005-11-24 |
2009-04-30 |
ラボラトワ セローノ エス.エイ. |
エリスロポエチンポリペプチド及びそれらの使用
|
EP3026109B1
(en)
*
|
2005-12-08 |
2022-03-09 |
Amgen Inc. |
Improved production of glycoproteins using manganese
|
EP1974014B1
(en)
|
2006-01-04 |
2017-04-19 |
Baxalta Incorporated |
Oligopeptide-free cell culture media
|
DE102006004008A1
(de)
|
2006-01-27 |
2007-08-02 |
Hannelore Prof. Dr. Dr. Ehrenreich |
Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
EP2004211A4
(en)
*
|
2006-03-17 |
2010-07-07 |
Stem Cell Therapeutics Corp |
DOSEERSCHEMATA FOR LH OR HCG AND EPO FOR THE TREATMENT OF NEUROLOGICAL DISEASES
|
EP1997505A4
(en)
|
2006-03-22 |
2013-02-13 |
Chugai Pharmaceutical Co Ltd |
PREPARATION OF ERYTHROPOIETIN SOLUTION
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
***在预防或治疗视网膜损伤中的用途
|
PT2038252T
(pt)
|
2006-07-12 |
2016-12-16 |
Univ Tennessee Res Found |
Acilanilidos substituidos e métodos de utilização dos mesmos
|
US8765924B2
(en)
|
2006-08-04 |
2014-07-01 |
Prolong Pharmaceuticals, Inc. |
Modified erythropoietin
|
CA2661054A1
(en)
|
2006-08-22 |
2008-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Prophylactic and/or therapeutic agents for peripheral neuropathy
|
EA016853B1
(ru)
|
2006-08-24 |
2012-08-30 |
Юниверсити Оф Теннесси Рисерч Фаундейшн |
Замещенные ациланилиды и их применение
|
AU2007294858B2
(en)
*
|
2006-09-14 |
2011-05-12 |
Medgenics Medical Israel, Ltd |
Long lasting drug formulations
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
CA2666789C
(en)
*
|
2006-10-18 |
2016-11-22 |
Yong Zhao |
Embryonic-like stem cells derived from adult human peripheral blood and methods of use
|
CN101678079B
(zh)
|
2006-11-28 |
2013-12-25 |
韩诺生物制约株式会社 |
修饰的***多肽及其治疗用途
|
WO2008068879A1
(en)
*
|
2006-12-06 |
2008-06-12 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human erythropoietin
|
US20100115638A1
(en)
*
|
2006-12-19 |
2010-05-06 |
Amina Abina |
Method for inhibiting the expression of endogenous erythropoietin (epo)
|
US8629250B2
(en)
*
|
2007-02-02 |
2014-01-14 |
Amgen Inc. |
Hepcidin, hepcidin antagonists and methods of use
|
AR065613A1
(es)
|
2007-03-09 |
2009-06-17 |
Chugai Pharmaceutical Co Ltd |
Agentes de proteccion para organos transplantados
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
AU2008261212A1
(en)
|
2007-06-15 |
2008-12-18 |
University Of Zurich |
Treatment for Alzheimer' s disease
|
WO2009010107A1
(en)
|
2007-07-19 |
2009-01-22 |
Hannelore Ehrenreich |
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
|
BRPI0814465B1
(pt)
|
2007-07-26 |
2021-11-23 |
Novagen Holding Corporation |
Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
CA2701032C
(en)
|
2007-09-27 |
2021-01-26 |
Amgen Inc. |
Pharmaceutical formulations
|
WO2009064838A1
(en)
|
2007-11-15 |
2009-05-22 |
Amgen, Inc. |
Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
EP2574628B1
(en)
|
2008-01-25 |
2015-05-20 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
AU2009218069B2
(en)
|
2008-02-27 |
2014-05-01 |
Fuso Pharmaceutical Industries, Ltd. |
Expression vector for mass production of foreign gene-derived protein using animal cell and use thereof
|
EP2095829A1
(en)
|
2008-02-27 |
2009-09-02 |
LEK Pharmaceuticals D.D. |
Selenium containing modifying agents and conjugates
|
WO2009139822A1
(en)
|
2008-05-01 |
2009-11-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
DE102008002210A1
(de)
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur fermentativen Herstellung von Erythropoietin
|
DE102008002209A1
(de)
|
2008-06-04 |
2009-12-10 |
Evonik Degussa Gmbh |
Verfahren zur Aufreinigung von Erythropoietin
|
US8003689B2
(en)
*
|
2008-06-20 |
2011-08-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
WO2010034442A1
(en)
|
2008-09-23 |
2010-04-01 |
F. Hoffmann-La Roche Ag |
Purification of erythropoietin
|
WO2010036964A2
(en)
|
2008-09-26 |
2010-04-01 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
CN102215869B
(zh)
|
2008-11-13 |
2015-05-13 |
通用医疗公司 |
用于通过调整bmp-6来调节铁稳态的方法和组合物
|
DE102008054716A1
(de)
|
2008-12-16 |
2010-06-17 |
Evonik Degussa Gmbh |
Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
|
CA2748011C
(en)
|
2008-12-22 |
2019-02-26 |
National University Corporation Hokkaido University |
Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof
|
US20100272816A1
(en)
|
2009-04-27 |
2010-10-28 |
Wolfgang Rudinger |
Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
|
CN107083400A
(zh)
|
2009-05-02 |
2017-08-22 |
建新公司 |
神经退行性疾病的基因治疗
|
EP2480569B1
(en)
|
2009-09-23 |
2016-04-13 |
ratiopharm GmbH |
Process for the purification of recombinant human erythropoietin (epo)
|
AU2010310457B2
(en)
|
2009-10-23 |
2015-07-02 |
Amgen Inc. |
Vial adapter and system
|
KR20180037303A
(ko)
|
2010-06-07 |
2018-04-11 |
암젠 인크 |
약물 전달 장치
|
AU2011268458B2
(en)
|
2010-06-15 |
2014-06-12 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
CA2813038C
(en)
|
2010-09-28 |
2021-12-28 |
Amylin Pharmaceuticals, Llc |
Highly soluble leptins
|
CA2831100C
(en)
|
2011-03-31 |
2020-02-18 |
Mark Dominis Holt |
Vial adapter and system
|
CA2833748C
(en)
|
2011-04-20 |
2019-07-16 |
Amgen Inc. |
Autoinjector apparatus
|
PT3045189T
(pt)
|
2011-10-14 |
2018-07-23 |
Amgen Inc |
Injetor e método de montagem
|
KR101443257B1
(ko)
|
2011-10-18 |
2014-09-19 |
주식회사 종근당 |
낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
US9241869B2
(en)
|
2011-10-25 |
2016-01-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
IN2015DN01046A
(es)
|
2012-07-13 |
2015-06-26 |
Gtx Inc |
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US9650411B2
(en)
|
2012-08-07 |
2017-05-16 |
Kyowa Hakko Kirin Co., Ltd. |
Method of purifying protein
|
WO2014062535A1
(en)
|
2012-10-15 |
2014-04-24 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
MX2015006343A
(es)
|
2012-11-21 |
2015-10-05 |
Amgen Inc |
Dispositivo de administracion de farmacos.
|
ES2797974T3
(es)
*
|
2013-03-14 |
2020-12-04 |
Translate Bio Inc |
Acidos ribonucleicos con nucleótidos modificados con 4-tio y procedimientos relacionados
|
WO2014138921A1
(en)
|
2013-03-15 |
2014-09-18 |
Apotex Inc. |
Enhanced liquid formulation stability of erythropoietin alpha through purification processing
|
EP2968760B1
(en)
|
2013-03-15 |
2024-01-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
ES2695166T3
(es)
|
2013-03-15 |
2019-01-02 |
Intrinsic Lifesciences Llc |
Anticuerpos antihepcidina y usos de los mismos
|
JP6768501B2
(ja)
|
2013-03-15 |
2020-10-14 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入機、および自動注入機システム
|
KR102287687B1
(ko)
|
2013-03-22 |
2021-08-06 |
암젠 인크 |
인젝터 및 조립 방법
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10196601B2
(en)
|
2013-08-20 |
2019-02-05 |
Lek Pharmaceuticals D.D. |
Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides
|
EP3501575B1
(en)
|
2013-10-24 |
2021-12-01 |
Amgen Inc. |
Drug delivery system with temperature-sensitive-control
|
JP7086520B2
(ja)
|
2013-10-24 |
2022-06-20 |
アムジエン・インコーポレーテツド |
インジェクター及び組み立ての方法
|
US20150118187A1
(en)
|
2013-10-24 |
2015-04-30 |
Medgenics Medical Israel Ltd. |
Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
WO2015171777A1
(en)
|
2014-05-07 |
2015-11-12 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
KR20230037063A
(ko)
|
2014-06-03 |
2023-03-15 |
암겐 인코포레이티드 |
제어 가능한 약물 전달 시스템 및 사용 방법
|
WO2016049036A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
WO2016061220A2
(en)
|
2014-10-14 |
2016-04-21 |
Amgen Inc. |
Drug injection device with visual and audio indicators
|
ES2898469T3
(es)
|
2014-12-19 |
2022-03-07 |
Amgen Inc |
Dispositivo de administración de medicamentos con sensor de proximidad
|
EP3233159B1
(en)
|
2014-12-19 |
2020-03-04 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
EP3556411B1
(en)
|
2015-02-17 |
2021-06-30 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
EP3981450A1
(en)
|
2015-02-27 |
2022-04-13 |
Amgen, Inc |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
WO2017068051A1
(en)
|
2015-10-21 |
2017-04-27 |
Lek Pharmaceuticals D.D. |
Peg-based dendron and process for producing the same
|
WO2017100501A1
(en)
|
2015-12-09 |
2017-06-15 |
Amgen Inc. |
Auto-injector with signaling cap
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
EP3429663B1
(en)
|
2016-03-15 |
2020-07-15 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
US11541168B2
(en)
|
2016-04-29 |
2023-01-03 |
Amgen Inc. |
Drug delivery device with messaging label
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
WO2017197222A1
(en)
|
2016-05-13 |
2017-11-16 |
Amgen Inc. |
Vial sleeve assembly
|
WO2017200989A1
(en)
|
2016-05-16 |
2017-11-23 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
WO2017209899A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
US11285266B2
(en)
|
2016-07-01 |
2022-03-29 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
EP3532127A1
(en)
|
2016-10-25 |
2019-09-04 |
Amgen Inc. |
On-body injector
|
AU2018210301A1
(en)
|
2017-01-17 |
2019-08-01 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
CA3048520A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
MX2019009755A
(es)
|
2017-02-17 |
2019-10-07 |
Amgen Inc |
Mecanismo de insercion para dispositivo de suministro de farmacos.
|
MX2019010544A
(es)
|
2017-03-06 |
2019-10-21 |
Amgen Inc |
Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
|
SG11201908058UA
(en)
|
2017-03-07 |
2019-09-27 |
Amgen Inc |
Needle insertion by overpressure
|
SG11201908062QA
(en)
|
2017-03-09 |
2019-09-27 |
Amgen Inc |
Insertion mechanism for drug delivery device
|
EP3570871B1
(en)
|
2017-03-20 |
2020-11-18 |
H. Hoffnabb-La Roche Ag |
Method for in vitro glycoengineering of an erythropoiesis stimulating protein
|
LT3600491T
(lt)
|
2017-03-28 |
2023-10-10 |
Amgen Inc. |
Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
|
AU2018280054B2
(en)
|
2017-06-08 |
2023-07-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
AU2018282077B2
(en)
|
2017-06-08 |
2023-11-23 |
Amgen Inc. |
Torque driven drug delivery device
|
KR102268647B1
(ko)
|
2017-06-12 |
2021-06-23 |
한국코러스 주식회사 |
안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법
|
US11541183B2
(en)
|
2017-06-22 |
2023-01-03 |
Amgen Inc. |
Device activation impact/shock reduction
|
CA3063921A1
(en)
|
2017-06-23 |
2018-12-27 |
Amgen Inc. |
Electronic drug delivery device comprising a cap activated by a switch assembly
|
JP7408398B2
(ja)
|
2017-07-14 |
2024-01-05 |
アムジエン・インコーポレーテツド |
二重ねじりばねシステムを有する針挿入後退システム
|
JP2020527376A
(ja)
|
2017-07-21 |
2020-09-10 |
アムジエン・インコーポレーテツド |
薬物容器のためのガス透過性シーリング部材及び組立方法
|
EP4085942A1
(en)
|
2017-07-25 |
2022-11-09 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
EP3658206A1
(en)
|
2017-07-25 |
2020-06-03 |
Amgen Inc. |
Drug delivery device with container access system and related method of assembly
|
US20200164155A1
(en)
|
2017-08-09 |
2020-05-28 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
EP3668567A1
(en)
|
2017-08-18 |
2020-06-24 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
WO2019070472A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
|
MA50614A
(fr)
|
2017-10-06 |
2020-08-12 |
Amgen Inc |
Dispositif d'administration de médicament comprenant un ensemble de verrouillage et procédé d'assemblage associé
|
WO2019074579A1
(en)
|
2017-10-09 |
2019-04-18 |
Amgen Inc. |
DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF
|
US11826480B2
(en)
|
2017-11-03 |
2023-11-28 |
Amgen Inc. |
Systems and approaches for sterilizing a drug delivery device
|
US20200261648A1
(en)
|
2017-11-06 |
2020-08-20 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
US20200338271A1
(en)
|
2017-11-06 |
2020-10-29 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
AU2018364933B2
(en)
|
2017-11-10 |
2024-01-25 |
Amgen Inc. |
Plungers for drug delivery devices
|
MX2020005066A
(es)
|
2017-11-16 |
2020-08-20 |
Amgen Inc |
Autoinyector con deteccion de detencion y punto final.
|
JP7370969B2
(ja)
|
2017-11-16 |
2023-10-30 |
アムジエン・インコーポレーテツド |
薬物送達デバイスの扉ラッチ機構
|
KR20210013036A
(ko)
|
2018-05-24 |
2021-02-03 |
국립대학법인 홋가이도 다이가쿠 |
신규 벡터 및 그 이용
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
US20210260279A1
(en)
|
2018-07-24 |
2021-08-26 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
MA53379A
(fr)
|
2018-07-24 |
2021-06-02 |
Amgen Inc |
Dispositifs d'administration pour l'administration de médicaments
|
CA3103682A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
EP3829692A1
(en)
|
2018-07-31 |
2021-06-09 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
MA53724A
(fr)
|
2018-09-24 |
2021-12-29 |
Amgen Inc |
Systèmes et procédés de dosage interventionnel
|
US20210228811A1
(en)
|
2018-09-28 |
2021-07-29 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
CN112805048B
(zh)
|
2018-10-02 |
2023-09-22 |
安进公司 |
具有内部力传递的用于药物递送的注射***
|
MA53818A
(fr)
|
2018-10-05 |
2022-01-12 |
Amgen Inc |
Dispositif d'administration de médicament ayant un indicateur de dose
|
EP3866890A1
(en)
|
2018-10-15 |
2021-08-25 |
Amgen Inc. |
Drug delivery device having damping mechanism
|
EA202191038A1
(ru)
|
2018-10-15 |
2021-07-06 |
Эмджен Инк. |
Способ платформенной сборки для устройства доставки лекарственного средства
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
CA3113076A1
(en)
|
2018-11-01 |
2020-05-07 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
WO2020091956A1
(en)
|
2018-11-01 |
2020-05-07 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
WO2020219482A1
(en)
|
2019-04-24 |
2020-10-29 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
EP4017560A2
(en)
|
2019-08-23 |
2022-06-29 |
Amgen, Inc |
Drug delivery device with configurable needle shield engagement components and related methods
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
CN117320964A
(zh)
|
2021-05-21 |
2023-12-29 |
美国安进公司 |
优化药物容器的灌装方案的方法
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023209074A1
(en)
|
2022-04-28 |
2023-11-02 |
Institut National de la Santé et de la Recherche Médicale |
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
|
WO2024094457A1
(en)
|
2022-11-02 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Method for producing glycoprotein compositions
|